Format
Sort by

Send to

Choose Destination

Search results

Items: 13

1.
2.

Indole-3-carbinol disrupts estrogen receptor-alpha dependent expression of insulin-like growth factor-1 receptor and insulin receptor substrate-1 and proliferation of human breast cancer cells.

Marconett CN, Singhal AK, Sundar SN, Firestone GL.

Mol Cell Endocrinol. 2012 Nov 5;363(1-2):74-84. doi: 10.1016/j.mce.2012.07.008. Epub 2012 Jul 24.

3.

Antiproliferative effects of artemisinin on human breast cancer cells requires the downregulated expression of the E2F1 transcription factor and loss of E2F1-target cell cycle genes.

Tin AS, Sundar SN, Tran KQ, Park AH, Poindexter KM, Firestone GL.

Anticancer Drugs. 2012 Apr;23(4):370-9. doi: 10.1097/CAD.0b013e32834f6ea8.

PMID:
22185819
4.

Indole-3-carbinol downregulation of telomerase gene expression requires the inhibition of estrogen receptor-alpha and Sp1 transcription factor interactions within the hTERT promoter and mediates the G1 cell cycle arrest of human breast cancer cells.

Marconett CN, Sundar SN, Tseng M, Tin AS, Tran KQ, Mahuron KM, Bjeldanes LF, Firestone GL.

Carcinogenesis. 2011 Sep;32(9):1315-23. doi: 10.1093/carcin/bgr116. Epub 2011 Jun 21.

5.
6.

BZL101, a phytochemical extract from the Scutellaria barbata plant, disrupts proliferation of human breast and prostate cancer cells through distinct mechanisms dependent on the cancer cell phenotype.

Marconett CN, Morgenstern TJ, San Roman AK, Sundar SN, Singhal AK, Firestone GL.

Cancer Biol Ther. 2010 Aug 15;10(4):397-405. Epub 2010 Aug 20.

7.

1-Benzyl-indole-3-carbinol is a novel indole-3-carbinol derivative with significantly enhanced potency of anti-proliferative and anti-estrogenic properties in human breast cancer cells.

Nguyen HH, Lavrenov SN, Sundar SN, Nguyen DH, Tseng M, Marconett CN, Kung J, Staub RE, Preobrazhenskaya MN, Bjeldanes LF, Firestone GL.

Chem Biol Interact. 2010 Aug 5;186(3):255-66. doi: 10.1016/j.cbi.2010.05.015. Epub 2010 Jun 2.

8.

Indole-3-carbinol triggers aryl hydrocarbon receptor-dependent estrogen receptor (ER)alpha protein degradation in breast cancer cells disrupting an ERalpha-GATA3 transcriptional cross-regulatory loop.

Marconett CN, Sundar SN, Poindexter KM, Stueve TR, Bjeldanes LF, Firestone GL.

Mol Biol Cell. 2010 Apr 1;21(7):1166-77. doi: 10.1091/mbc.E09-08-0689. Epub 2010 Feb 3.

9.

Anticancer activities of artemisinin and its bioactive derivatives.

Firestone GL, Sundar SN.

Expert Rev Mol Med. 2009 Oct 30;11:e32. doi: 10.1017/S1462399409001239. Review.

PMID:
19883518
10.

Minireview: modulation of hormone receptor signaling by dietary anticancer indoles.

Firestone GL, Sundar SN.

Mol Endocrinol. 2009 Dec;23(12):1940-7. doi: 10.1210/me.2009-0149. Epub 2009 Oct 16. Review.

11.

Artemisinin blocks prostate cancer growth and cell cycle progression by disrupting Sp1 interactions with the cyclin-dependent kinase-4 (CDK4) promoter and inhibiting CDK4 gene expression.

Willoughby JA Sr, Sundar SN, Cheung M, Tin AS, Modiano J, Firestone GL.

J Biol Chem. 2009 Jan 23;284(4):2203-13. doi: 10.1074/jbc.M804491200. Epub 2008 Nov 17.

12.

Artemisinin selectively decreases functional levels of estrogen receptor-alpha and ablates estrogen-induced proliferation in human breast cancer cells.

Sundar SN, Marconett CN, Doan VB, Willoughby JA Sr, Firestone GL.

Carcinogenesis. 2008 Dec;29(12):2252-8. doi: 10.1093/carcin/bgn214. Epub 2008 Sep 10.

13.

Indole-3-carbinol selectively uncouples expression and activity of estrogen receptor subtypes in human breast cancer cells.

Sundar SN, Kerekatte V, Equinozio CN, Doan VB, Bjeldanes LF, Firestone GL.

Mol Endocrinol. 2006 Dec;20(12):3070-82. Epub 2006 Aug 10.

PMID:
16901971
Items per page

Supplemental Content

Loading ...
Write to the Help Desk